Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, ...

Abbott (NYSE:ABT) today reported Street-beating second-quarter results that included significant growth in its Diabetes ...

Discover Abbott Laboratories' Q2 2025 highlights: resilience drives high single-digit growth, double-digit EPS, and pipeline innovations.

Abbott beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its medical devices, including continuous glucose monitors.

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

Abbott’s ABT diversified business portfolio appears to be well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving ABT Shares Within ...

Abbott announced results from its REFLECT real-world studies that show the use of FreeStyle Libre continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk ...

(RTTNews) - Abbott Laboratories (ABT) Thursday announced positive data from REFLECT studies of its FreeStyle Libre continuous glucose monitoring (CGM) technology.

Abbott’s FreeStyle Libre technology, known for its user-friendly design and broad accessibility, complements our innovative system.” ...

MANCHESTER, N.H., March 18, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced that Abbott’s FreeStyle Libre 3 ...